When MACI becomes the right next step for an ankle cartilage lesion

If your consultant has told you that your ankle cartilage damage is too large or too deep for a straightforward marrow-stimulation procedure, you are likely in the territory where matrix-induced autologous chondrocyte implantation — MACI — deserves consideration.

The ankle cartilage repair pathway runs from symptom management and biologic support through to cartilage restoration procedures and, at the far end, joint replacement. MACI sits firmly in the cartilage restoration tier — a cell-based technique designed for defects that simpler approaches cannot reliably address.

The critical dividing line is defect size. Microfracture performs well for small ankle lesions, but data from two large clinical series — Chuckpaiwong et al. (2008, 105 patients) and Choi et al. (2009, 168 lesions) — show near-total failure once a defect exceeds roughly 15 mm in average diameter or 150 mm² on MRI. Beyond that threshold, cell-based repair becomes the more appropriate strategy, and MACI is one of the most established options in that space.

The patients who typically reach this decision point are younger and active, with a focal, full-thickness lesion producing symptoms significant enough to warrant a restoration procedure rather than management alone. What determines whether MACI is the right choice within that window — rather than a single-stage alternative — includes factors such as lower-limb alignment, whether a previous procedure has already been attempted, and the precise location of the lesion within the talus.

The defect size threshold that separates MACI from microfracture

The numbers behind that size threshold are striking. Chuckpaiwong and colleagues (2008, 105 patients) found that microfracture for talar lesions with an average diameter under 15 mm produced no failures — yet once that diameter reached 15 mm or more, 97% of treatments failed. Choi et al. (2009, 168 lesions) confirmed a comparable boundary using MRI-measured area: reliable success was confined to defects below 150 mm². Beyond that point, marrow stimulation does not simply underperform — it largely fails.

The reason lies partly in biology and partly in mechanics. Microfracture works by recruiting a marrow clot into the defect; at greater surface areas, that clot becomes progressively unstable. The repair tissue it produces is fibrocartilage rather than the hyaline-like tissue of healthy articular cartilage, and published series document deterioration in this fibrocartilage at around two to three years. There is a further cost: disrupting the subchondral bone plate can complicate any subsequent repair attempt, narrowing the options if the first procedure fails.

Maci-treated defects in the published evidence base ranged from 1.21 to 3.4 cm² (mean approximately 204 mm²), placing them consistently above both cut-offs. This alignment is not coincidental — MACI enters the algorithm where marrow stimulation has already demonstrated it cannot reliably succeed.

Knee-based data from the SUMMIT RCT support cell-based repair over bone marrow stimulation for defects of 3 cm² or more; this principle is applied by inference to the ankle, as no equivalent ankle-specific randomised trial exists.

Who is a candidate: grading, age, alignment, and prior treatment

Candidacy for MACI rests on several factors assessed together, not on any single criterion applied in isolation.

Cartilage grade

MACI targets full-thickness articular cartilage damage — specifically lesions graded Outerbridge III–IV or ICRS III–IV (cartilage that has eroded all the way down to, or through to, bone) and Hepple grade 3–4 on MRI. Partial-thickness lesions do not typically meet this threshold.

Age and activity

Published cohorts have involved patients aged approximately 18 to 46 years. This reflects a practical logic: MACI is a cartilage-preservation strategy, and its value is greatest when enough healthy joint remains and the patient's activity goals justify a two-stage commitment.

Lower-limb alignment

Varus alignment is associated with medial talar lesions, which account for around 83% of talar osteochondral defects. Malalignment left uncorrected can undermine any cartilage repair over time, so whole-leg alignment is assessed before a surgical plan is finalised; a corrective procedure may be considered alongside implantation.

Prior treatment history

A previous microfracture does not automatically exclude a patient, but any disruption to the subchondral bone plate alters the repair environment and is reviewed individually.

Lesion location

Where a defect sits on the talus influences surgical access. Posterior or shoulder lesions may require a medial malleolar osteotomy to reach the defect adequately — a meaningful planning and counselling consideration before any decision is reached.

What the two-stage MACI procedure involves

MACI unfolds across two separate procedures with a laboratory interval between them.

Stage one is an arthroscopic biopsy, usually performed as a day-case under general or regional anaesthetic. A small quantity of cartilage is harvested from a non-weight-bearing region of the ankle joint. The sample is then sent to a specialist laboratory, where chondrocytes are isolated, expanded in culture, and seeded onto a Type I/III collagen membrane scaffold — a purpose-designed matrix that distinguishes MACI from first-generation ACI, which relied on a periosteal patch to contain the cells.

Stage two, typically several weeks later, is the implantation. The chondrocyte-seeded membrane is trimmed to fit the prepared defect bed in the talus and fixed in place. Where the defect sits on the posterior dome or a shoulder region, achieving adequate surgical exposure may require a medial malleolar osteotomy — a temporary division of the inner ankle bone that is later stabilised with screws, and which carries its own recovery implications beyond those of the cartilage repair itself.

In practical terms, the pathway involves two separate anaesthetics, two rehabilitation periods, and a waiting phase in between. That procedural burden is one of the factors weighed against single-stage alternatives such as AMIC, discussed later in this article.

What outcomes to realistically expect

Functional scores improve consistently across published series. The AOFAS scale — a 100-point measure of ankle pain, function, and alignment — rose from pre-operative means of 36.9–70.1 to post-operative means of 78.3–95.3 across nine studies in the 2025 systematic review of 166 patients. That breadth partly reflects how varied patients are at the starting point: a score of 37 represents meaningful functional limitation, while 70 indicates someone still managing moderate activity despite pain.

Long-term durability is supported by a 15-patient case series followed to a mean of 12.9 years, with a mean treated defect of 204 mm². AOFAS remained at 84 at that stage, and FAAM-ADL — a functional activity score specific to the foot and ankle — reached 89%. In carefully selected patients, the repair appears to hold over a decade.

Return to sport ranged from 50% to 82.4% across three studies; return to general activity was 81.8% in one further series. The spread reflects differences in patient selection and sport level rather than inconsistency in the technique itself, so a single figure would misrepresent the evidence.

Complication and revision rates run from 0–59% and 0–45% respectively. Those spans are very wide because they pool 11 small, heterogeneous series — some involving only a handful of patients followed briefly, others with longer observation. The 12.9-year series, the most durable available, recorded sustained functional outcomes, which puts the upper end of those ranges in context.

On what improved scores mean in practice: the question patients reasonably ask is whether the change was large enough to feel different day-to-day. None of the included studies reported a minimum clinically important difference or patient-acceptable symptom threshold, so while scores clearly rise, how that translates to individual goals — returning to a specific sport, walking without pain on uneven ground — is something a consultant can work through at assessment.

MACI alongside other options: AMIC, candidacy nuance, and where to get assessed

The most directly relevant comparator to MACI is autologous matrix-induced chondrogenesis (AMIC) — a single-stage procedure that combines microfracture with immediate application of a collagen scaffold, recruiting the patient's own progenitor cells without any cartilage harvest or laboratory expansion phase. Midterm evidence suggests AMIC achieves comparable clinical outcomes to MACI while avoiding the biopsy, the waiting interval, and the second anaesthetic that define the two-stage pathway. For many patients, that difference in procedural burden is substantive rather than marginal.

MACI's theoretical advantage lies in delivering expanded, matrix-seeded chondrocytes directly to the lesion — a more biologically intensive repair that may be favourable in particularly large or complex defects. The 12.9-year case series noted outcomes that are 'equivalent' to other established methods, including mosaicplasty, rather than superior — and arrived at that result at higher cost and greater procedural complexity. No ankle-specific randomised trial has compared MACI head-to-head with either AMIC or microfracture; all comparative framing at the ankle depends on historical cohorts or inference from knee data, and should be understood accordingly.

What this means in practice is that choosing between MACI and AMIC is not automatic — it turns on individual factors: the defect's size and location, the patient's activity demands, tolerance for repeat surgery, and what has already been attempted. That is precisely the conversation a structured consultant assessment is designed to have. The MSK Doctors team at Sleaford and Grantham sees ankle cartilage cases without GP referral; assessments can be arranged directly at mskdoctors.com.

1. [1] Favorable Short-Term Outcomes of Matrix-Associated Autologous Chondrocyte Implantation (MACI) for Osteochondral Lesions of the Talus: A Systematic Review. (2025). https://doi.org/10.1016/j.arthro.2025.07.045 https://doi.org/10.1016/j.arthro.2025.07.045
2. [2] Matrix-induced autologous chondrocyte implantation versus autologous matrix-induced chondrogenesis for chondral defects of the talus: a systematic review. (2021). https://doi.org/10.1093/bmb/ldab008 https://doi.org/10.1093/bmb/ldab008
3. [3] Matrix-Induced Autologous Chondrocyte Implantation (MACI) Grafting for Osteochondral Lesions of the Talus. (2020). https://doi.org/10.1177/1071100720935110 https://doi.org/10.1177/1071100720935110
4. [4] Treatment of Osteochondral Lesions of the Talus With Matrix-induced Autologous Chondrocyte Implantation (MACI). (2020). https://doi.org/10.1097/BTF.0000000000000276 https://doi.org/10.1097/BTF.0000000000000276
5. [5] Autologous Chondrocyte Implantation as a Secondary Procedure after Failed Microfracture for Osteochondral Lesion of Talus. (2015). https://doi.org/10.14193/JKFAS.2015.19.1.7 https://doi.org/10.14193/JKFAS.2015.19.1.7
6. [6] Lower limb malalignment on whole-leg radiography predicts medial or lateral talar osteochondral lesion location. (2025). https://doi.org/10.1016/j.ocarto.2025.100707 https://doi.org/10.1016/j.ocarto.2025.100707